Australian medical robotics company Vexev has raised $6 million in new funding to accelerate the path to FDA 510(k) clearance and US commercialisation of VxWave, its robotic tomographic ultrasound platform, designed to improve access to standardised vascular imaging. The raise brings Vexev's total funding to date to $19 million.
Cardiovascular disease is the world's leading cause of death, claiming nearly 20 million lives each year. Yet access to high-quality vascular imaging remains constrained by specialist availability and inconsistent image acquisition. Vexev is developing autonomous robotic imaging technology designed to help address that challenge.
VxWave combines robotics, artificial intelligence and ultrasound imaging to automate vascular ultrasound acquisition. The platform is being developed for upper-limb imaging, with dialysis vascular access as its initial application, where patients require frequent vascular monitoring and healthcare providers face increasing demand for efficient, standardized imaging.
The fundraise round included participation from existing investors Blackbird Ventures, Neotribe Ventures, Startmate and Horizon, together with new investors TreeArc Investment Group, TEN13, Bioshore Ventures and Alumni Ventures. Funding will support regulatory activities, manufacturing scale-up and commercialisation.
